Eikon’s lead candidate EIK1001 is being investigated for melanoma in combination with MSD’s Keytruda in a Phase III trial.

The lead Eikon drug, EIK1001, is a small molecule designed to hit toll-like receptors 7 and 8 (TLR7/8). Activating these receptors is intended to spark an immune response that fights cancer.

However, Mounjaro belongs to a class of drugs called dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Kidney problems have been ...

Researchers found that the rate difference of depression was 3.48 per 1000 person-years between GLP-1 RA users and SGLT-2i users. HealthDay News — For older adults with type 2 diabetes (T2D ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are ...

Toll-like receptor. Toll-like receptors (TLRs) are one of the largest and best-studied families of pattern-recognition receptors of the innate immune system. TLRs recognize pathogen- and danger ...

STING/TLR-agonist Antibody-Drug Conjugates and mRNA technologies You will also have the opportunity to ask any burning questions and go back to your teams with a full picture of the innate ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Beijing Synthetic Vaccine Biosciences Co. Ltd. has synthesized Toll-like receptor 8 (TLR8) agonists reported to be useful for the treatment of autoimmune disease, cancer, inflammatory disorders and ...